Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could tame tough eczema by calming overactive immune cells

NCT ID NCT07711418

Disease control Sponsor: Nektar Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear or nearly clear the skin and reduce eczema severity over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called rezpegaldesleukin (NKTR-358) given as a shot under the skin
What this could lead to
If successful, this could provide a new treatment option for people with moderate-to-severe atopic dermatitis, potentially offering better symptom control with fewer side effects than current therapies.
What could go wrong
This is an early-stage Phase 3 trial, and the drug may not prove more effective than placebo. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 510 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline * Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms ≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit * Patients must meet the following AD severity criteria: * IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline * ≥ 10.0% of BSA involvement at Screening and Baseline * EASI ≥ 16.0 at Screening and Baseline * Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy * Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives Exclusion Criteria: * Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy * Are currently experiencing or have a history of unstable course of AD * History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit. * Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal * Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD * Have a current or recent acute, active infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Nektar Investigative Site

    RECRUITING

    Birmingham, Alabama, 35203, United States

  • Nektar Investigative Site

    RECRUITING

    Oxnard, California, 93030, United States

  • Nektar Investigative Site

    RECRUITING

    Palmdale, California, 93551, United States

  • Nektar Investigative Site

    RECRUITING

    Sacramento, California, 95815, United States

  • Nektar Investigative Site

    RECRUITING

    Tamarac, Florida, 33321, United States

  • Nektar Investigative Site

    RECRUITING

    Savannah, Georgia, 31406, United States

  • Nektar Investigative Site

    RECRUITING

    Metairie, Louisiana, 70006, United States

  • Nektar Investigative Site

    RECRUITING

    Kirksville, Missouri, 63501, United States

  • Nektar Investigative Site

    RECRUITING

    Lee's Summit, Missouri, 64064, United States

  • Nektar Investigative Site

    RECRUITING

    Las Vegas, Nevada, 89144, United States

  • Nektar Investigative Site

    RECRUITING

    Robbinsville, New Jersey, 08691, United States

  • Nektar Investigative Site

    RECRUITING

    The Bronx, New York, 10455, United States

  • Nektar Investigative Site

    RECRUITING

    Columbus, Ohio, 43213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.